Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorCalle, Myriam
dc.contributor.authorMiravitlles Fernández, Marc
dc.contributor.authorMichel de la Rosa, Francisco Javier
dc.contributor.authorHernandez Perez, JM
dc.contributor.authorMontero Martínez, Carmen
dc.contributor.authorMontoro Ronsano, J. Bruno
dc.contributor.authorLópez-Campos Bodineau, José Luis
dc.date.accessioned2023-03-03T08:18:47Z
dc.date.available2023-03-03T08:18:47Z
dc.date.issued2023-01-30
dc.identifier.citationCalle Rubio M, López-Campos JL, Miravitlles M, de la Rosa FJM, Hernández Pérez JM, Montero Martínez C,, et al. COVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients. BMC Health Serv Res. 2023 Jan 30;23:98.
dc.identifier.issn1472-6963
dc.identifier.urihttps://hdl.handle.net/11351/9101
dc.descriptionAlpha-1-antitrypsin deficiency; COVID-19; Patient management
dc.description.abstractBackground Patients with alpha-1 antitrypsin deficiency (AATD), commonly categorized as a rare disease, have been affected by the changes in healthcare management brought about by COVID-19. This study’s aim was to identify the changes that have taken place in AATD patient care as a result of the COVID-19 pandemic in Spain and to propose experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. Methods A qualitative descriptive case study with a holistic single-case design was conducted, using focus groups with experts in AATD clinical management, including 15 health professionals with ties to the Spanish health system (12 pneumologists and 2 hospital pharmacists from 11 different hospitals in Spain) and 1 patient representative. Results COVID-19 has had a major impact on numerous aspects of AATD clinical patient management in Spain, including diagnostic, treatment, and follow-up phases. The experts concluded that there is a need to strengthen coordination between Primary Care and Hospital Care and improve the coordination processes across all the organizations and actors involved in the healthcare system. Regarding telemedicine and telecare, experts have concluded that it is necessary to promote this methodology and to develop protocols and training programs. Experts have recommended developing personalized and precision medicine, and patient participation in decision-making, promoting self-care and patient autonomy to optimize their healthcare and improve their quality of life. The possibility of monitoring and treating AATD patients from home has also been proposed by experts. Another result of the study was the recommendation of the need to ensure that plasma donations are made on a regular basis by a sufficient number of healthy individuals. Conclusion The study advances knowledge by highlighting the challenges faced by health professionals and changes in AATD patient management in the context of the COVID-19 pandemic. It also proposes experts’ recommendations aimed at ensuring humanized and quality care for people with AATD in the post-pandemic situation. This work could serve as a reference study for physicians on their daily clinical practice with AATD patients and may also provide guidance on the changes to be put in place for the post-pandemic situation.
dc.language.isoeng
dc.publisherBMC
dc.relation.ispartofseriesBMC Health Services Research;23
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectCOVID-19 (Malaltia)
dc.subjectAlfa 1-antitripsina
dc.subjectPulmons - Malalties
dc.subjectAtenció centrada en el pacient
dc.subject.meshalpha 1-Antitrypsin Deficiency
dc.subject.meshCoronavirus Infections
dc.subject.meshDelivery of Health Care
dc.titleCOVID-19’s impact on care practice for alpha-1-antitrypsin deficiency patients
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1186/s12913-023-09094-3
dc.subject.decsdeficiencia de alfa 1-antitripsina
dc.subject.decsinfecciones por Coronavirus
dc.subject.decsprestación sanitaria
dc.relation.publishversionhttps://doi.org/10.1186/s12913-023-09094-3
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Calle Rubio M] Pulmonology Department, Health Research Institute of the Hospital Clínico San Carlos (IdISSC), San Carlos Clinical Hospital, Madrid, Spain. Department of Medicine, School of Medicine, Universidad Complutense de Madrid, Madrid, Spain. [López-Campos JL] Medical Surgical Unit for Respiratory Diseases, Biomedicine Institute of Sevilla (IBiS), Virgen del Rocío University Hospital, Seville, Spain. [Miravitlles M] Servei de Pneumologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Network of Centers for Biomedical Research On Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain. [Michel de la Rosa FJ] Pulmonology Department, Donostia University Hospital, San Sebastián, Spain. [Hernández Pérez JM] Network of Centers for Biomedical Research On Respiratory Diseases (CIBERES), Carlos III Health Institute, Madrid, Spain. Pulmonology Department, Nuestra Señora de Candelaria University Hospital, Santa Cruz de Tenerife, Spain. [Montero Martínez C] Pulmonology Department, A Coruña University Hospital, A Coruña, Spain. [Montoro Ronsano JB] Servei de Farmàcia, Vall d’Hebron Hospital Universitari, Barcelona, Spain
dc.identifier.pmid36717880
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record